glp-1 and dementia GLP-1R agonists protect against Alzheimer's disease by rewiring energy regulation Association between glucagon‐like peptide‐1 receptor

Most GLP-1 medications are given via subcutaneous injection, which means an injection under the skin but not in the muscle

Others opt for evening or night-time injections, particularly if they experience mild gastrointestinal side effects, though this approach is based on anecdotal experience rather than clinical evidence, especially for once-weekly formulations

Annals of Medicine & Surgery

D.PhillipsM.AsztalosB.BittmanR.et al (2011)

The Meds vs

The study is registered in PROSPERO: Similar content being viewed by others 1 Introduction Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used in the treatment of diabetes mellitus (DM) and obesity [1, 2]